Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Latigo Biotherapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Latigo Biotherapeutics, Inc.’s stock price such as:

• Latigo Biotherapeutics, Inc.’s current stock price and volume
• Why Latigo Biotherapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for LTGO from analysts
• LTGO’s stock price momentum as measured by its relative strength

About Latigo Biotherapeutics, Inc. (LTGO)

Before we jump into Latigo Biotherapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

Want to learn more about Latigo Biotherapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Latigo Biotherapeutics, Inc..

Latigo Biotherapeutics, Inc.’s Stock Price as of Market Close

As of October 22, 2026, 9:59 AM, CST, Latigo Biotherapeutics, Inc.’s stock price was $16.565.

Latigo Biotherapeutics, Inc. is up 1.38% from its previous closing price of $16.340.

During the last market session, Latigo Biotherapeutics, Inc.’s stock traded between $16.190 and $16.640. Currently, there are approximately 0.94 million shares outstanding for Latigo Biotherapeutics, Inc..

Latigo Biotherapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Latigo Biotherapeutics, Inc. Stock Price History

Latigo Biotherapeutics, Inc.’s (LTGO) price is currently down 0.81% so far this month.

During the month of October, Latigo Biotherapeutics, Inc.’s stock price has reached a high of $17.550 and a low of $13.498.

Over the last year, Latigo Biotherapeutics, Inc. has hit prices as high as $25.930 and as low as $13.498.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Latigo Biotherapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 21, 2026, there were analysts who downgraded Latigo Biotherapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Latigo Biotherapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Latigo Biotherapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Latigo Biotherapeutics, Inc. (LTGO) by visiting AAII Stock Evaluator.

Relative Price Strength of Latigo Biotherapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 21, 2026, Latigo Biotherapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Latigo Biotherapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Latigo Biotherapeutics, Inc. Stock Price: Bottom Line

As of October 22, 2026, Latigo Biotherapeutics, Inc.’s stock price is $16.565, which is up 1.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Latigo Biotherapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.